IDEXX Laboratories Misses on Q2 Earnings, Issues FY22 Guidance Below Consensus
IDEXX Laboratories Inc (NASDAQ: IDXX ) reported Q2 revenues of $861 million , an increase of 4% Y|Y on a reported basis and 6.5% on an organic basis, missing the consensus of $864.61 million. The growth is driven by Companion Animal Group (CAG) Diagnostics'' recurring revenue growth of 4% reported and 7% organic. U.S. same-store clinical visits at veterinary practices declined 3% … Full story available on Benzinga.com
IDEXX Laboratories Misses on Q2 Earnings, Issues FY22 Guidance Below Consensus
IDEXX Laboratories Inc (NASDAQ: IDXX ) reported Q2 revenues of $861 million , an increase of 4% Y|Y on a reported basis and 6.5% on an organic basis, missing the consensus of $864.61 million. The growth is driven by Companion Animal Group (CAG) Diagnostics'' recurring revenue growth of 4% reported and 7% organic. U.S. same-store clinical visits at veterinary practices declined 3% … Full story available on Benzinga.com